Business Description

Description
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 7.5
Equity-to-Asset 0.75
Debt-to-Equity 0.17
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 20.68
Distress
Grey
Safe
Beneish M-Score -52.62
Manipulator
Not Manipulator

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.13
Quick Ratio 7.96
Days Inventory 20
Days Payable 145

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 95.14
Operating Margin % -37555.21
Net Margin % -39118.06
FCF Margin % -26539.69
ROE % -101.25
ROA % -72.72
ROC (Joel Greenblatt) % -6301.11

Financials

FRA:KYT's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

KYTHERA Biopharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0.257
EPS (TTM) (€) -4.063
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR (€) 0
20-Day SMA (€) 0
12-1 Month Momentum % 0
52-Week Range (€) 24.49 - 68.48
Shares Outstanding (Mil) 26.27

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

KYTHERA Biopharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

KYTHERA Biopharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

KYTHERA Biopharmaceuticals Inc Frequently Asked Questions

What is KYTHERA Biopharmaceuticals Inc(FRA:KYT)'s stock price today?
The current price of FRA:KYT is €66.74. The 52 week high of FRA:KYT is €68.48 and 52 week low is €24.49.
When is next earnings date of KYTHERA Biopharmaceuticals Inc(FRA:KYT)?
The next earnings date of KYTHERA Biopharmaceuticals Inc(FRA:KYT) is .
Does KYTHERA Biopharmaceuticals Inc(FRA:KYT) pay dividends? If so, how much?
KYTHERA Biopharmaceuticals Inc(FRA:KYT) does not pay dividend.

Press Release

Subject Date
No Press Release